Clinical trials
Recurrence clinical trials
Below are recruiting recurrence clinical trials, each written for real people, not researchers. We’re tracking 1,423 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06532799RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer
This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.
Beijing, Beijing MunicipalityAges 16–90 - NCT06537193Recruiting
Shorter MRI vs CT scan to check for liver cancer return
This trial compares a shorter MRI using a special dye to a CT scan for detecting liver cancer recurrence in people who have been cancer-free for at least two years after surgery or local treatment.
Seoul, Songpa-gu , 88, Olympic-ro 43-gilAges 20 years+ - NCT06538480RecruitingPhase 4
Zopa retreatment study for recurrent respiratory papillomatosis
This trial tests if people with recurrent respiratory papillomatosis (growths in the airway caused by HPV) can safely get more doses of the study drug Zopa and checks if the virus spreads after treatment. It may help people who have already tried Zopa or are considering it for the first time.
Atlanta, GeorgiaAges 18 years+ - NCT06538012RecruitingPhase 1/Phase 2
Tumor immune cells plus pembrolizumab for advanced lung cancer
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
Beijing, Beijing MunicipalityAges 16–90 - NCT06540729RecruitingPhase 2
RC48, AK104, and Bevacizumab for Ovarian Clear Cell Cancer
This trial tests a combination of three drugs: RC48 (targets HER2), AK104 (a PD-1/CTLA-4 blocker), and bevacizumab (a blood vessel growth blocker) for ovarian clear cell carcinoma. It may be an option for women whose tumors have low levels of HER2 and who have not had immunotherapy before, after up to two prior chemotherapies.
Guanzhou, GuangdongAges 18–75 - NCT06556732RecruitingPhase 1
Eplerenone for preventing atrial fibrillation return
This trial is testing whether a medication called eplerenone can help prevent atrial fibrillation (AF) from coming back in people who have structural heart disease and have already had their heart rhythm restored to normal. It may be a good option if you are looking for a way to keep your heart in a normal rhythm.
AsyutAges 20–70 - NCT06557889RecruitingPhase 2
Fewer chemo cycles with immunotherapy for head and neck cancer
This study tests whether giving fewer chemotherapy cycles combined with the immunotherapy drug pembrolizumab works as well as the standard full course of chemo plus pembrolizumab for head and neck cancer that has come back or spread. It is for people whose tumors have the PD-L1 protein.
AmiensAges 18 years+ - NCT06561178Recruiting
Blood Test to Monitor Esophageal Cancer After Surgery
This trial looks at whether a personalized blood test can detect cancer returning after surgery for esophageal cancer. It tests people who had chemoradiotherapy before surgery and still had some cancer remaining in the removed tissue. The goal is to use the blood test to catch any remaining or returning cancer early.
Guangzhou, GuangdongAges Any age - NCT06577272Recruiting
Predicting cancer return after tumor ablation
This study looks at people with liver cancer who are treated with a procedure called radiofrequency ablation (RFA). It aims to create a tool that can predict the chance of the cancer coming back after treatment.
Hangzhou, ZhejiangAges Any age - NCT06584565Recruiting
Predicting stroke recovery and risk using blood and stool tests
This study uses advanced analysis of your blood and stool samples to better predict how you will recover from a stroke and whether it might happen again. It aims to help doctors personalize your care after a stroke.
Guangzhou, GuangdongAges 18–75 - NCT06585527RecruitingPhase 1
TS-2021 for recurrent malignant brain tumors
This trial tests the safety and effectiveness of a new drug called TS-2021 for people whose high-grade brain tumor has come back after initial treatment. It may be an option if you previously had surgery, radiation, or chemotherapy and are now facing a recurrence.
Beijing, Beijing MunicipalityAges 18–65 - NCT06587802RecruitingPhase 2
PD-1 antibody and radiation for advanced adrenal cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT06593977Recruiting
Dynavisc gel for pain after repeat carpal tunnel surgery
This trial tests a gel called Dynavisc to see if it reduces pain when placed in the wrist during a second surgery for carpal tunnel syndrome. It may help people who still have pain after their first surgery.
Leuven, BelgiumAges 18–65 - NCT07690579Recruiting
Prostate cancer disparities study
This study looks at how social, lifestyle, and other factors affect prostate cancer outcomes. It enrolls men who have chosen to have their prostate removed (radical prostatectomy) and agreed to join a biobank.
San Francisco, CaliforniaAges 18 years+ - NCT07174661Recruiting
Planning ahead for teens and young adults with advanced cancer
This study tests an educational tool to help young adults with advanced solid tumors or high-grade brain tumors think about and discuss their future healthcare wishes early. It may help you feel more prepared and in control of your care.
Scottsdale, ArizonaAges 18–39 - NCT03934372RecruitingPhase 1/Phase 2
Ponatinib for children with relapsed or hard-to-treat cancers
This trial tests a targeted therapy called ponatinib in children whose leukemia, lymphoma, or solid tumor has come back or hasn't improved with standard treatments. The drug works by blocking signals that help cancer cells grow, and the study looks at how safe and effective it is for different cancer types.
GhentAges 1–17 - NCT06096038RecruitingPhase 1
CAR-T cell therapy for head and neck cancer
This trial tests a new treatment using your own immune cells (CAR-T cells) to target a protein called CSPG4 found on head and neck cancer cells. It is for people whose cancer has come back or not responded to other treatments.
Chapel Hill, North CarolinaAges 18 years+ - NCT07657312RecruitingPhase 2
Infliximab to prevent side effects during myeloma treatment
This trial tests if infliximab, a drug that calms the immune system, can prevent cytokine release syndrome (a serious side effect) when patients receive teclistamab or talquetamab for multiple myeloma that has returned or not responded to treatment.
Columbus, OhioAges 18 years+ - NCT07613645Recruiting
Lifestyle changes to prevent recurring C. difficile infection
This study tests whether specific lifestyle changes during treatment for C. difficile infection (a serious gut bacteria infection) can help prevent it from coming back. You'll receive standard antibiotic treatment and follow a controlled diet while researchers track your recovery.
Ann Arbor, MichiganAges 18 years+ - NCT06601335RecruitingPhase 3
New immunotherapy combo for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (AK112 and AK117) versus the standard immunotherapy pembrolizumab for people with advanced head and neck cancer that hasn't been treated before.
Wuhan, HubeiAges 18–75 - NCT06608394Recruiting
Exercise habits and knee recovery after ACL surgery
This study looks at how your exercise habits before surgery might affect your knee function and the chance of re-injury after anterior cruciate ligament (ACL) reconstruction. It aims to help doctors give better advice on post-surgery rehabilitation.
Beijing, Beijing MunicipalityAges 18–45 - NCT06613841RecruitingEarly Phase 1
Brain tumor imaging study for glioblastoma patients
This study uses special PET scans (fluciclovine and FDG) and advanced MRI to create a detailed metabolic profile of glioblastoma. It may help doctors better understand your tumor before surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06614647Recruiting
Digital follow-up for colorectal cancer survivors
This trial tests a smartphone-based follow-up program for people who have been treated for early-stage colorectal cancer. The goal is to see if a digital, need-based care guide can replace standard follow-up visits.
Herning, Central JutlandAges 18 years+ - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Daphne, AlabamaAges 18 years+
Hear when a new Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrence?
- Yes. Clin2 currently lists 1,423 recruiting recurrence studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrence trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrence trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.